Ernexa Therapeutics (ERNA) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $3.0 million.
- Ernexa Therapeutics' Cash & Equivalents fell 2854.13% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 2854.13%. This contributed to the annual value of $1.7 million for FY2024, which is 8518.42% down from last year.
- As of Q3 2025, Ernexa Therapeutics' Cash & Equivalents stood at $3.0 million, which was down 2854.13% from $4.3 million recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Cash & Equivalents ranged from a high of $50.2 million in Q2 2021 and a low of $1.7 million during Q4 2024
- Its 5-year average for Cash & Equivalents is $12.3 million, with a median of $8.9 million in 2023.
- In the last 5 years, Ernexa Therapeutics' Cash & Equivalents skyrocketed by 86719.0% in 2021 and then tumbled by 8518.42% in 2024.
- Ernexa Therapeutics' Cash & Equivalents (Quarter) stood at $24.4 million in 2021, then tumbled by 36.26% to $15.5 million in 2022, then dropped by 24.91% to $11.7 million in 2023, then crashed by 85.18% to $1.7 million in 2024, then surged by 76.23% to $3.0 million in 2025.
- Its Cash & Equivalents was $3.0 million in Q3 2025, compared to $4.3 million in Q2 2025 and $1.9 million in Q1 2025.